BRIEF-Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy

Nurix Therapeutics

Nurix Therapeutics

NRIX

0.00

June 11 (Reuters) - Nurix Therapeutics Inc NRIX.O:

  • NURIX THERAPEUTICS TO REPORT UPDATED PHASE 1A/B RESULTS FOR BTK DEGRADER BEXOBRUTIDEG, HIGHLIGHTING DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL AND PROMISING ACTIVITY IN EARLIER LINES OF THERAPY

  • NURIX THERAPEUTICS - REPORTS 92.9% OBJECTIVE RESPONSE RATE IN SECOND LINE BTKI-EXPOSED, BCL2I-NAÏVE CLL PATIENTS

  • NURIX THERAPEUTICS - PHASE 1A DATA SHOWS 22.1 MONTH MEDIAN PFS, 83% ORR IN HEAVILY PRETREATED RELAPSED/REFRACTORY CLL/SLL

  • NURIX THERAPEUTICS - BEXOBRUTIDEG WELL TOLERATED WITH CONSISTENT SAFETY PROFILE

  • NURIX THERAPEUTICS - RESPONSES OBSERVED IN HIGH-RISK, BTK RESISTANT, AND CNS-INVOLVED CLL SUBGROUPS

Source text: ID:nGNX6Z6fqX

Further company coverage: NRIX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.